

an introduction to

MEDICINAL CHEMISTRY

Seventh Edition

GRAHAM L. PATRICK

OXFORD
UNIVERSITY PRESS

Detailed contents

1 Drugs and drug targets: an overview	1
1.1 What is a drug?	1
1.2 Drug targets	3
1.2.1 Cell structure	3
1.2.2 Drug targets at the molecular level	4
1.3 Intermolecular bonding forces	5
1.3.1 Electrostatic or ionic bonds	5
1.3.2 Hydrogen bonds	5
1.3.2.1 Conventional hydrogen bonds	5
1.3.2.2 Unconventional hydrogen bonds	7
1.3.3 Van der Waals interactions	8
1.3.4 Dipole–dipole, ion–dipole, and cation– π interactions	8
1.3.5 π – π interactions	9
1.3.6 Halogen bonds	10
1.3.7 Repulsive interactions	10
1.3.8 The role of water and hydrophobic interactions	11
1.4 Pharmacokinetic issues and medicines	11
1.5 Classification of drugs	12
1.5.1 By pharmacological effect	12
1.5.2 By chemical structure	12
1.5.3 By target system	12
1.5.4 By target molecule	12
1.6 Naming of drugs and medicines	13

Part A Drug targets: structure and function

2 Protein structure and function	17
2.1 The primary structure of proteins	17
2.2 The secondary structure of proteins	17
2.2.1 The α -helix	18
2.2.2 The β -pleated sheet	19
2.2.3 The β -turn	19
2.3 The tertiary structure of proteins	19
2.3.1 Covalent bonds: disulphide links	20
2.3.2 Ionic or electrostatic bonds	20
2.3.3 Hydrogen bonds	20
2.3.4 Van der Waals and hydrophobic interactions	21
2.3.5 Relative importance of bonding interactions	22
2.3.6 Role of the planar peptide bond	23
2.4 The quaternary structure of proteins	24
2.5 Translation and post-translational modifications	24
2.6 Proteomics	24
2.7 Protein function	26
2.7.1 Structural proteins	26
2.7.2 Transport proteins	26
2.7.3 Enzymes and receptors	27
2.7.4 Miscellaneous proteins and protein–protein interactions	27

3 Enzymes: structure and function	29
3.1 Enzymes as catalysts	29
3.2 How do enzymes catalyse reactions?	30
3.3 The active site of an enzyme	30
3.4 Substrate binding at an active site	30
3.5 The catalytic role of enzymes	31
3.5.1 Binding interactions	31
3.5.2 Acid/base catalysis	32
3.5.3 Nucleophilic groups	32
3.5.4 Stabilization of the transition state	33
3.5.5 Cofactors	34
3.5.6 Naming and classification of enzymes	35
3.5.7 Genetic polymorphism and enzymes	35
3.6 Regulation of enzymes	36
3.7 Isozymes	37
3.8 Enzyme kinetics	39
3.8.1 The Michaelis–Menten equation	39
3.8.2 Lineweaver–Burk plots	40
Box 3.1 The external control of enzymes by nitric oxide	38
4 Receptors: structure and function	42
4.1 Role of the receptor	42
4.2 Neurotransmitters and hormones	42
4.3 Receptor types and subtypes	44
4.4 Receptor activation	45
4.5 How does the binding site change shape?	45
4.6 Ion channel receptors	46
4.6.1 General principles	46
4.6.2 Structure	47
4.6.3 Gating	48
4.6.4 Ligand-gated and voltage-gated ion channels	49
4.7 G-Protein-coupled receptors	49
4.7.1 General principles	49
4.7.2 Structure of G-protein-coupled receptors	50
4.7.3 The rhodopsin-like family of G-protein-coupled receptors	50
4.7.4 Dimerization of G-coupled receptors	52
4.8 Kinase receptors	52
4.8.1 General principles	52
4.8.2 Structure of tyrosine kinase receptors	53
4.8.3 Activation mechanism for tyrosine kinase receptors	53
4.8.4 Tyrosine kinase receptors as targets in drug discovery	54
4.8.4.1 The ErbB family of tyrosine kinase receptors	54
4.8.4.2 Vascular endothelial growth factor receptors	54
4.8.4.3 Platelet-derived growth factor receptors	54
4.8.4.4 Stem cell growth factor receptors	54
4.8.4.5 Anaplastic lymphoma kinase	55
4.8.4.6 The RET receptor	55
4.8.4.7 Hepatocyte growth factor receptor or c-MET receptor	55

4.9	Intracellular receptors	55
4.10	Regulation of receptor activity	56
4.11	Genetic polymorphism and receptors	56
5	Receptors and signal transduction	58
5.1	Signal transduction pathways for G-protein-coupled receptors (GPCRs)	58
5.1.1	Interaction of the receptor–ligand complex with G-proteins	58
5.1.2	Signal transduction pathways involving the α -subunit	58
5.2	Signal transduction involving G-proteins and adenylate cyclase	60
5.2.1	Activation of adenylate cyclase by the α_s -subunit	60
5.2.2	Activation of protein kinase A	60
5.2.3	The G_i -protein	61
5.2.4	General points about the signalling cascade involving cyclic AMP	62
5.2.5	The role of the $\beta\gamma$ -dimer	63
5.2.6	Phosphorylation	63
5.3	Signal transduction involving G-proteins and phospholipase C_β	64
5.3.1	G-Protein effect on phospholipase C_β	64
5.3.2	Action of the secondary messenger: diacylglycerol	64
5.3.3	Action of the secondary messenger: inositol triphosphate	65
5.3.4	Resynthesis of phosphatidylinositol diphosphate	65
5.4	The role of β -arrestins in modulating the activity of G-protein-coupled receptors	66
5.5	Signal transduction involving kinase receptors	67
5.5.1	Activation of signalling proteins and enzymes	67
5.5.2	The MAPK signal transduction pathway	67
5.5.3	Activation of guanylate cyclase by kinase receptors	69
5.5.4	The JAK-STAT signal transduction pathway	69
5.5.5	The PI3K/Akt/mTOR signal transduction pathway	70
5.6	The hedgehog signalling pathway	71
6	Nucleic acids: structure and function	73
6.1	Structure of DNA	73
6.1.1	The primary structure of DNA	73
6.1.2	The secondary structure of DNA	73
6.1.3	The tertiary structure of DNA	74
6.1.4	Chromatins	76
6.1.5	Genetic polymorphism and personalized medicine	77
6.2	Ribonucleic acid and protein synthesis	78
6.2.1	Structure of RNA	78
6.2.2	Transcription and translation	78
6.2.3	Small nuclear RNA	79
6.2.4	The regulatory role of RNA	81
6.3	Genetic illnesses	81
6.4	Molecular biology and genetic engineering	82

Part B	Pharmacodynamics and pharmacokinetics	
7	Enzymes as drug targets	89
7.1	Inhibitors acting at the active site of an enzyme	89
7.1.1	Reversible inhibitors	89
7.1.2	Irreversible inhibitors	90
7.2	Inhibitors acting at allosteric binding sites	92
7.3	Uncompetitive and non-competitive inhibitors	92
7.4	Transition-state analogues: renin inhibitors	92
7.5	Suicide substrates	93
7.6	Isozyme selectivity of inhibitors	95
7.7	Medicinal uses of enzyme inhibitors	96
7.7.1	Enzyme inhibitors used against microorganisms	96
7.7.2	Enzyme inhibitors used against viruses	97
7.7.3	Enzyme inhibitors used against the body's own enzymes	97
7.7.4	Enzyme modulators	98
7.8	Enzyme kinetics	99
7.8.1	Lineweaver–Burk plots	99
7.8.2	Comparison of inhibitors	101
Box 7.1	A cure for antifreeze poisoning	90
Box 7.2	Irreversible inhibition for the treatment of obesity	91
Box 7.3	Suicide substrates	95
Box 7.4	Designing drugs to be isozyme selective	96
Box 7.5	Action of toxins on enzymes	98
Box 7.6	Kinase inhibitors	99
8	Receptors as drug targets	103
8.1	Introduction	103
8.2	The design of agonists	103
8.2.1	Binding groups	103
8.2.2	Position of the binding groups	104
8.2.3	Size and shape	105
8.2.4	Other design strategies	106
8.2.5	Pharmacodynamics and pharmacokinetics	107
8.2.6	Examples of agonists	107
8.2.7	Allosteric modulators	107
8.3	The design of antagonists	107
8.3.1	Antagonists acting at the binding site	107
8.3.2	Antagonists acting outside the binding site	110
8.4	Partial agonists	111
8.5	Inverse agonists	112
8.6	Desensitization and sensitization	112
8.7	Tolerance and dependence	114
8.8	Receptor types and subtypes	114
8.9	Affinity, efficacy, and potency	116
Box 8.1	An unexpected agonist	106
Box 8.2	Estradiol and the estrogen receptor	109

[illegible]

12.3.6	Screening by NMR	191	13.1.9	Binding role of esters	215
12.3.7	Affinity screening	192	13.1.10	Binding role of alkyl and aryl halides	215
12.3.8	Surface plasmon resonance	192	13.1.11	Binding role of thiols and ethers	216
12.3.9	Scintillation proximity assay	193	13.1.12	Binding role of phosphates, phosphonates, and phosphinates	216
12.3.10	Isothermal titration calorimetry	193	13.1.13	Binding role of other functional groups	217
12.3.11	Virtual screening	193	13.1.14	Binding role of alkyl groups and the carbon skeleton	217
12.4	Finding a lead compound	193	13.1.15	Binding role of heterocycles	217
12.4.1	Screening of natural products	194	13.1.16	Isosteres	218
12.4.1.1	The plant kingdom	194	13.1.17	Testing procedures	219
12.4.1.2	Microorganisms	194	13.1.18	SAR in drug optimization	220
12.4.1.3	Marine sources	195	13.2	Identification of a pharmacophore	220
12.4.1.4	Animal sources	195	13.3	Drug optimization: strategies in drug design	221
12.4.1.5	Venoms and toxins	195	13.3.1	Variation of substituents	221
12.4.2	Medical folklore	196	13.3.1.1	Alkyl substituents	221
12.4.3	Screening synthetic compound 'libraries'	196	13.3.1.2	Substituents on aromatic or heteroaromatic rings	223
12.4.4	Existing drugs	197	13.3.1.3	Varying substituents to change the pK_a of ionizable groups	224
12.4.4.1	'Me too' and 'me better' drugs	197	13.3.1.4	Synergistic effects	224
12.4.4.2	Enhancing a side effect	197	13.3.2	Extension of the structure	224
12.4.5	Starting from the natural ligand or modulator	198	13.3.3	Chain extension/contraction	226
12.4.5.1	Natural ligands for receptors	198	13.3.4	Ring expansion/contraction	226
12.4.5.2	Natural substrates for enzymes	199	13.3.5	Ring variations	227
12.4.5.3	Enzyme products as lead compounds	200	13.3.6	Ring fusions	228
12.4.5.4	Natural modulators as lead compounds	200	13.3.7	Isosteres and bio-isosteres	228
12.4.6	Combinatorial and parallel synthesis	200	13.3.8	Simplification of the structure	229
12.4.7	Computer-aided design of lead compounds	200	13.3.9	Rigidification of the structure	231
12.4.8	Serendipity and the prepared mind	200	13.3.10	Conformational blockers	233
12.4.9	Computerized searching of structural databases	202	13.3.11	Rigidification through intramolecular bonds	234
12.4.10	Fragment-based lead discovery	202	13.3.12	Structure-based drug design and molecular modelling	235
12.4.11	Properties of lead compounds	204	13.3.13	Drug design by NMR spectroscopy	235
12.5	Isolation and purification	206	13.3.14	The elements of luck and inspiration	235
12.6	Structure determination	206	13.3.15	Designing drugs to interact with more than one target	236
12.7	Herbal medicine	206	13.3.15.1	Agents designed from known drugs	237
Box 12.1	Recently discovered targets: the caspases	186	13.3.15.2	Agents designed from non-selective lead compounds	237
Box 12.2	Pitfalls in choosing particular targets	188	13.4	Selectivity	237
Box 12.3	Early tests for potential toxicity	189	13.5	Pharmacokinetics	238
Box 12.4	Selective optimization of side activities (SOSA)	199	Box 13.1	Converting an enzyme substrate to an inhibitor by extension tactics	225
Box 12.5	Natural ligands as lead compounds	200	Box 13.2	Simplification	230
Box 12.6	Examples of serendipity	201	Box 13.3	Rigidification tactics in drug design	233
Box 12.7	The use of NMR spectroscopy in finding lead compounds	203	Box 13.4	The structure-based drug design of crizotinib	236
Box 12.8	Click chemistry <i>in situ</i>	204	13	Drug design: optimizing target interactions	209
Box 12.9	Fragment-based design of a scaffold using X-ray crystallography	205	13.1	Structure-activity relationships	209
13	Drug design: optimizing target interactions	209	13.1.1	Binding role of alcohols and phenols	209
13.1	Structure-activity relationships	209	13.1.2	Binding role of aromatic rings	211
13.1.1	Binding role of alcohols and phenols	209	13.1.3	Binding role of alkenes	211
13.1.2	Binding role of aromatic rings	211	13.1.4	Binding role of ketones and aldehydes	211
13.1.3	Binding role of alkenes	211	13.1.5	Binding role of amines	212
13.1.4	Binding role of ketones and aldehydes	211	13.1.6	Binding role of amides	213
13.1.5	Binding role of amines	212	13.1.7	Binding role of quaternary ammonium salts	214
13.1.6	Binding role of amides	213	13.1.8	Binding role of carboxylic acids	214
13.1.7	Binding role of quaternary ammonium salts	214	14	Drug design: optimizing access to the target	241
13.1.8	Binding role of carboxylic acids	214	14.1	Optimizing hydrophilic/hydrophobic properties	241
			14.1.1	Masking polar functional groups to decrease polarity	241
			14.1.2	Adding or removing polar functional groups to vary polarity	242
			14.1.3	Varying hydrophobic substituents to vary polarity	242
			14.1.4	Variation of <i>N</i> -alkyl substituents to vary pK_a	243
			14.1.5	Other structural variations affecting pK_a	243
			14.1.6	Bio-isosteres for polar groups involved in binding interactions	243

xvi Detailed contents

14.2 Making drugs more resistant to chemical and enzymatic degradation	244	15 Getting the drug to market	265
14.2.1 Steric shields	244	15.1 Preclinical and clinical trials	265
14.2.2 Electronic effects of bio-isosteres and substituents	244	15.1.1 Toxicity testing	265
14.2.3 Steric and electronic modifications	245	15.1.2 Drug metabolism studies	266
14.2.4 Metabolic blockers	245	15.1.3 Pharmacology, formulation, and stability tests	267
14.2.5 Removal or replacement of susceptible metabolic groups	245	15.1.4 Clinical trials	268
14.2.6 Group shifts	246	15.1.4.1 Phase I studies	268
14.2.7 Ring variation and ring substituents	247	15.1.4.2 Phase II studies	269
14.3 Making drugs less resistant to drug metabolism	247	15.1.4.3 Phase III studies	269
14.3.1 Introducing metabolically susceptible groups	247	15.1.4.4 Phase IV studies	269
14.3.2 Self-destruct drugs	248	15.1.4.5 Ethical issues	270
14.4 Targeting drugs	249	15.2 Patenting and regulatory affairs	271
14.4.1 Targeting tumour cells: 'search and destroy' drugs	249	15.2.1 Patents	271
14.4.2 Targeting gastrointestinal infections	249	15.2.2 Regulatory affairs	272
14.4.3 Targeting peripheral regions rather than the central nervous system	249	15.2.2.1 The regulatory process	272
14.4.4 Targeting with membrane tethers	249	15.2.2.2 Fast-tracking and orphan drugs	273
14.4.5 Targeting antibacterial agents using siderophores	249	15.2.2.3 Good laboratory, manufacturing, and clinical practice	273
14.5 Reducing toxicity	250	15.2.2.4 Cost-versus-benefit analysis	274
14.6 Prodrugs	251	15.3 Chemical and process development	274
14.6.1 Prodrugs to improve membrane permeability	251	15.3.1 Chemical development	274
14.6.1.1 Esters as prodrugs	251	15.3.2 Process development	275
14.6.1.2 <i>N</i> -Methylated prodrugs	252	15.3.3 Choice of drug candidate	278
14.6.1.3 Trojan horse approach for transport proteins	253	15.3.4 Natural products	278
14.6.2 Prodrugs to prolong drug activity	253	Box 15.1 Drug metabolism studies and drug design	267
14.6.3 Prodrugs masking drug toxicity and side effects	253	Box 15.2 Synthesis of ebalzotan	276
14.6.4 Prodrugs to lower water solubility	255	Box 15.3 Synthesis of ICI D7114	276
14.6.5 Prodrugs to improve water solubility	255	■ Case study 2 The design of ACE inhibitors	281
14.6.6 Prodrugs used in the targeting of drugs	256	■ Case study 3 Artemisinin and related antimalarial drugs	288
14.6.7 Prodrugs to increase chemical stability	256	■ Case study 4 The design of oxamniquine	294
14.6.8 Prodrugs activated by external influence (sleeping agents)	256	■ Case study 5 Fosmidomycin as an antimalarial agent	300
14.7 Drug alliances	257		
14.7.1 'Sentry' drugs	257		
14.7.2 Localizing a drug's area of activity	257		
14.7.3 Increasing absorption	257		
14.8 Endogenous compounds as drugs	257		
14.8.1 Neurotransmitters	258		
14.8.2 Natural hormones, peptides, and proteins as drugs	258		
14.9 Peptides and peptidomimetics in drug design	259		
14.9.1 Peptidomimetics	260		
14.9.2 Peptide drugs	261		
14.10 Oligonucleotides as drugs	262		
Box 14.1 The use of bio-isosteres to increase absorption	244		
Box 14.2 Shortening the lifetime of a drug	248		
Box 14.3 Identifying and replacing potentially toxic groups	250		
Box 14.4 Varying esters in prodrugs	252		
Box 14.5 Prodrugs masking toxicity and side effects	254		
Box 14.6 Prodrugs to improve water solubility	255		
		Part D Tools of the trade	
		16 Combinatorial and parallel synthesis	307
		16.1 Combinatorial and parallel synthesis in medicinal chemistry projects	307
		16.2 Solid-phase techniques	307
		16.2.1 The solid support	308
		16.2.2 The anchor/linker	309
		16.2.3 Examples of solid-phase syntheses	309
		16.3 Planning and designing a compound library	311
		16.3.1 'Spider-like' scaffolds	311
		16.3.2 Designing 'drug-like' molecules	312
		16.3.3 Synthesis of scaffolds	312
		16.3.4 Substituent variation	312
		16.3.5 Designing compound libraries for lead optimization	312
		16.3.6 Computer-designed libraries	312
		16.4 Testing for activity	314
		16.4.1 High-throughput screening	314
		16.4.2 Screening 'on bead' or 'off bead'	314
		16.5 Parallel synthesis	315
		16.5.1 Solid-phase extraction	315

16.5.2	The use of resins in solution phase organic synthesis (SPOS)	316	17.12.8	Docking of flexible ligands: anchor and grow programs	350
16.5.3	Reagents attached to solid support: catch and release	317	17.12.8.1	Directed Dock and Dock 4.0	350
16.5.4	Microwave technology	317	17.12.8.2	FlexX	350
16.5.5	Microfluidics in parallel synthesis	319	17.12.8.3	The Hammerhead program	351
16.6	Combinatorial synthesis	320	17.12.9	Docking of flexible ligands: simulated annealing and genetic algorithms	353
16.6.1	The mix and split method in combinatorial synthesis	320	17.13	Automated screening of databases for lead compounds and drug design	354
16.6.2	Structure determination of the active compound(s)	321	17.14	Protein mapping	354
16.6.2.1	Tagging	321	17.14.1	Constructing a model protein: homology modelling	354
16.6.2.2	Photolithography	323	17.14.2	Constructing a binding site: hypothetical pseudoreceptors	356
16.6.3	Dynamic combinatorial synthesis	323	17.15	<i>De novo</i> drug design	358
Box 16.1	Examples of scaffolds	313	17.15.1	General principles of <i>de novo</i> drug design	358
Box 16.2	Dynamic combinatorial synthesis of vancomycin dimers	324	17.15.2	Automated <i>de novo</i> drug design	359
17	<i>In silico</i> drug design	328	17.15.2.1	LUDI	359
17.1	Molecular and quantum mechanics	328	17.15.2.2	SPROUT	361
17.1.1	Molecular mechanics	328	17.15.2.3	LEGEND	364
17.1.2	Quantum mechanics	328	17.15.2.4	GROW, ALLEGROW, and SYNOPSIS	365
17.1.3	Choice of method	328	17.16	Planning compound libraries	366
17.2	Drawing chemical structures	329	17.17	Database handling	366
17.3	3D structures	329	Box 17.1	Energy minimization of apomorphine	330
17.4	Energy minimization	329	Box 17.2	Study of HOMO and LUMO orbitals	334
17.5	Viewing 3D molecules	330	Box 17.3	Finding conformations of cyclic structures by molecular dynamics	337
17.6	Molecular dimensions	331	Box 17.4	Identification of an active conformation	343
17.7	Molecular properties	331	Box 17.5	Constructing a receptor map	357
17.7.1	Partial charges	331	Box 17.6	Designing a non-steroidal glucocorticoid agonist	365
17.7.2	Molecular electrostatic potentials	332	18	Quantitative structure–activity relationships (QSAR)	369
17.7.3	Molecular orbitals	333	18.1	Graphs and equations	369
17.7.4	Spectroscopic transitions	333	18.2	Physicochemical properties	370
17.7.5	The use of grids in measuring molecular properties	335	18.2.1	Hydrophobicity	370
17.8	Conformational analysis	336	18.2.1.1	The partition coefficient (<i>P</i>)	370
17.8.1	Local and global energy minima	336	18.2.1.2	The substituent hydrophobicity constant (π)	372
17.8.2	Molecular dynamics	336	18.2.1.3	<i>P</i> versus π	373
17.8.3	Stepwise bond rotation	337	18.2.2	Electronic effects	373
17.8.4	Monte Carlo and the Metropolis method	338	18.2.3	Steric factors	376
17.8.5	Genetic and evolutionary algorithms	339	18.2.3.1	Taft's steric factor (E_s)	376
17.9	Structure comparisons and overlays	340	18.2.3.2	Molar refractivity	376
17.10	Identifying the active conformation	342	18.2.3.3	Verloop steric parameter	376
17.10.1	X-ray crystallography	342	18.2.4	Other physicochemical parameters	376
17.10.2	Comparison of rigid and non-rigid ligands	342	18.3	Hansch equation	377
17.11	3D pharmacophore identification	344	18.4	The Craig plot	378
17.11.1	X-ray crystallography	344	18.5	The Topliss scheme	378
17.11.2	Structural comparison of active compounds	344	18.6	Bio-isosteres	381
17.11.3	Automatic identification of pharmacophores	344	18.7	The Free–Wilson approach	381
17.12	Docking procedures	345	18.8	Planning a QSAR study	382
17.12.1	Manual docking	345	18.9	Case study: anti-allergic activity of a series of pyranenamines	382
17.12.2	Automatic docking	345	18.10	3D QSAR	384
17.12.3	Defining the molecular surface of a binding site	346	18.10.1	Defining steric and electrostatic fields	385
17.12.4	Rigid docking by shape complementarity	346	18.10.2	Relating shape and electronic distribution to biological activity	385
17.12.5	The use of grids in docking programs	349			
17.12.6	Rigid docking by matching hydrogen-bonding groups	349			
17.12.7	Rigid docking of flexible ligands: the FLOG program	350			

xviii Detailed contents

18.10.3	Advantages of CoMFA over traditional QSAR	386	19.5.3.1	Carbapenems	425
18.10.4	Potential problems of CoMFA	387	19.5.3.2	Monobactams	425
18.10.5	Other 3D QSAR methods	387	19.5.4	β -Lactamase inhibitors	427
18.10.6	Case study: inhibitors of tubulin polymerization	388	19.5.4.1	Clavulanic acid	427
Box 18.1	Altering log <i>P</i> to remove central nervous system side effects	372	19.5.4.2	Penicillanic acid sulphone derivatives	427
Box 18.2	Insecticidal activity of diethyl phenyl phosphates	375	19.5.4.3	Olivanic acids	427
Box 18.3	Hansch equation for a series of antimalarial compounds	377	19.5.4.4	β -Lactamase inhibitors lacking a β -lactam ring	428
■ Case study 6	Design of a thymidylate synthase inhibitor	391	19.5.5	Other drugs that act on bacterial cell wall biosynthesis	429
			19.5.5.1	D-Cycloserine and bacitracin	429
			19.5.5.2	The glycopeptides: vancomycin and vancomycin analogues	430
			19.6	Antibacterial agents that act on the plasma membrane structure	435
			19.6.1	Valinomycin and gramicidin A	435
			19.6.2	Polymyxin B	435
			19.6.3	Killer nanotubes	435
			19.6.4	Cyclic lipopeptides	435
			19.7	Antibacterial agents that impair protein synthesis: translation	436
			19.7.1	Aminoglycosides	436
			19.7.2	Tetracyclines	441
			19.7.3	Chloramphenicol	446
			19.7.4	Macrolides	446
			19.7.5	Lincosamides	447
			19.7.6	Streptogramins	447
			19.7.7	Oxazolidinones	447
			19.7.8	Pleuromutilins	449
			19.8	Agents that act on nucleic acid transcription and replication	451
			19.8.1	Quinolones and fluoroquinolones	451
			19.8.2	Spiropyrimidinetriones	453
			19.8.3	Aminoacridines	453
			19.8.4	Rifamycins	454
			19.8.5	Nitroimidazoles and nitrofurantoin	454
			19.8.6	Inhibitors of bacterial RNA polymerase	454
			19.9	Miscellaneous agents	456
			19.10	Antibodies	456
			19.11	Drug resistance	458
			19.11.1	Drug resistance by mutation	458
			19.11.2	Drug resistance by genetic transfer	459
			19.11.3	Other factors affecting drug resistance	459
			19.11.4	The way ahead	459
			Box 19.1	Sulphonamide analogues with reduced toxicity	401
			Box 19.2	Treatment of intestinal infections	402
			Box 19.3	Clinical properties of benzylpenicillin and phenoxymethylpenicillin	406
			Box 19.4	<i>Pseudomonas aeruginosa</i>	409
			Box 19.5	The isoxazolyl penicillins	414
			Box 19.6	Clinical aspects of β -lactamase-resistant penicillins	414
			Box 19.7	Ampicillin prodrugs	416
			Box 19.8	Clinical aspects of broad-spectrum penicillins	417
			Box 19.9	Synthesis of 3-methylated cephalosporins	421
			Box 19.10	Clinical aspects of cephalosporins	424
			Box 19.11	Clinical aspects of miscellaneous β -lactam antibiotics	426
19	Antibacterial agents	397			
19.1	History of antibacterial agents	397			
19.2	The bacterial cell	398			
19.3	Mechanisms of antibacterial action	399			
19.4	Antibacterial agents that act against cell metabolism (antimetabolites)	399			
19.4.1	Sulphonamides	399			
19.4.1.1	The history of sulphonamides	399			
19.4.1.2	Structure–activity relationships	400			
19.4.1.3	Sulphanilamide analogues	400			
19.4.1.4	Applications of sulphonamides	400			
19.4.1.5	Mechanism of action	400			
19.4.2	Examples of other antimetabolites	403			
19.4.2.1	Trimethoprim	403			
19.4.2.2	Sulphones	404			
19.5	Antibacterial agents that inhibit cell wall synthesis	404			
19.5.1	Penicillins	404			
19.5.1.1	History of penicillins	404			
19.5.1.2	Structure of benzylpenicillin and phenoxymethylpenicillin	405			
19.5.1.3	Properties of benzylpenicillin	405			
19.5.1.4	Mechanism of action for penicillin	406			
19.5.1.5	Resistance to penicillin	408			
19.5.1.6	Methods of synthesizing penicillin analogues	410			
19.5.1.7	Structure–activity relationships of penicillins	411			
19.5.1.8	Penicillin analogues	411			
19.5.1.9	Synergism of penicillins with other drugs	417			
19.5.2	Cephalosporins	418			
19.5.2.1	Cephalosporin C	418			
19.5.2.2	Synthesis of cephalosporin analogues at position 7	418			
19.5.2.3	First-generation cephalosporins	419			
19.5.2.4	Second-generation cephalosporins	420			
19.5.2.5	Third-generation cephalosporins	421			
19.5.2.6	Fourth-generation cephalosporins	422			
19.5.2.7	Fifth-generation cephalosporins	422			
19.5.2.8	Resistance to cephalosporins	424			
19.5.3	Other β -lactam antibiotics	425			

Box 19.12 Clinical aspects of cycloserine, bacitracin, and vancomycin	435	20.7.4.11 Alternative design strategies for antiviral drugs targeting the HIV protease enzyme	492
Box 19.13 Clinical aspects of drugs acting on the plasma membrane	436	20.7.5 Integrase inhibitors	492
Box 19.14 Clinical aspects of aminoglycosides	438	20.7.6 Cell entry inhibitors	494
Box 19.15 Synthesis of plazomicin	439	20.7.6.1 Fusion inhibitors targeting the viral gp41 glycoprotein	494
Box 19.16 Synthesis of minocycline and amadacycline	443	20.7.6.2 Inhibitors of the viral glycoprotein gp120	497
Box 19.17 Synthesis of eravacycline	444	20.7.6.3 Inhibitors of the host cell CD4 protein	500
Box 19.18 Clinical aspects of tetracyclines and chloramphenicol	445	20.7.6.4 Inhibitors of the host cell CCR5 chemokine receptor	500
Box 19.19 Clinical aspects of macrolides, lincosamides, streptogramins, oxazolidinones, and pleuromutilins	450	20.8 Antiviral drugs acting against RNA viruses: flu virus	501
Box 19.20 Synthesis of ciprofloxacin	452	20.8.1 Structure and life cycle of the influenza virus	501
Box 19.21 Clinical aspects of quinolones and fluoroquinolones	453	20.8.2 Ion channel disrupters: adamantanes	503
Box 19.22 Nitroimidazoles in the treatment of sleeping sickness	455	20.8.3 Neuraminidase inhibitors	504
Box 19.23 Clinical aspects of rifamycins and miscellaneous agents	457	20.8.3.1 Structure and mechanism of neuraminidase	504
Box 19.24 Organoarsenicals as antiparasitic drugs	461	20.8.3.2 Transition-state inhibitors: development of zanamivir (<i>Relenza</i> [™])	506
20 Antiviral agents	465	20.8.3.3 Transition-state inhibitors: 6-carboxamides	507
20.1 Viruses and viral diseases	465	20.8.3.4 Carbocyclic analogues: development of oseltamivir (<i>Tamiflu</i> [™])	508
20.2 Structure of viruses	465	20.8.3.5 Other ring systems	509
20.3 Life cycle of viruses	466	20.8.3.6 Resistance studies	510
20.4 Vaccination	466	20.8.4 Cap-dependent endonuclease inhibitors	510
20.5 Antiviral drugs: general principles	467	20.9 Antiviral drugs acting against RNA viruses: cold virus	513
20.6 Antiviral drugs used against DNA viruses	468	20.10 Antiviral drugs acting against RNA viruses: hepatitis C	514
20.6.1 Inhibitors of viral DNA polymerase	468	20.10.1 Inhibitors of HCV NS3-4A protease	514
20.6.2 Inhibitors of the DNA terminase complex	471	20.10.1.1 Introduction	514
20.6.3 Kinase inhibitors	471	20.10.1.2 Design of boceprevir and telaprevir	515
20.6.4 Inhibitors of tubulin polymerization	472	20.10.1.3 Second-generation protease inhibitors	516
20.6.5 Antisense therapy	472	20.10.2 Inhibitors of HCV NS5B RNA-dependent RNA polymerase	518
20.6.6 Antiviral drugs acting against hepatitis B	472	20.10.3 Inhibitors of HCV NS5A protein	518
20.7 Antiviral drugs acting against RNA viruses: the human immunodeficiency virus (HIV)	474	20.10.3.1 Symmetrical inhibitors	518
20.7.1 Structure and life cycle of HIV	474	20.10.3.2 Unsymmetrical inhibitors	521
20.7.2 Antiviral therapy against HIV	475	20.10.4 Other targets	522
20.7.3 Inhibitors of viral reverse transcriptase	476	20.11 Broad-spectrum antiviral agents	528
20.7.3.1 Nucleoside reverse transcriptase inhibitors	476	20.11.1 Agents acting against cytidine triphosphate synthetase	528
20.7.3.2 Non-nucleoside reverse transcriptase inhibitors	477	20.11.2 Agents acting against S-adenosylhomocysteine hydrolase	528
20.7.4 Protease inhibitors	480	20.11.3 Ribavirin	528
20.7.4.1 The HIV protease enzyme	481	20.11.4 Interferons	529
20.7.4.2 Design of HIV protease inhibitors	482	20.11.5 Antibodies and ribozymes	529
20.7.4.3 Saquinavir	483	20.11.5.1 Antibodies	529
20.7.4.4 Ritonavir and lopinavir	485	20.11.5.2 Ribozymes	529
20.7.4.5 Indinavir	487	20.12 Bioterrorism and smallpox	530
20.7.4.6 Nelfinavir	489	Box 20.1 Clinical aspects of inhibitors targeting viral DNA polymerase or the DNA terminase complex	472
20.7.4.7 Palinavir	490	Box 20.2 Clinical aspects of antiviral drugs used against HIV	476
20.7.4.8 Amprenavir and darunavir	490	Box 20.3 Clinical aspects of reverse transcriptase inhibitors	480
20.7.4.9 Atazanavir	491	Box 20.4 Clinical aspects of protease inhibitors	481
20.7.4.10 Tipranavir	491	Box 20.5 The use of a chiral centre to control the absolute configuration of a second chiral centre	495
		Box 20.6 Clinical aspects of integrase inhibitors	496

xx Detailed contents

Box 20.7	Clinical aspects of cell entry inhibitors	501	21.5.1	Agents that inhibit tubulin polymerization	564
Box 20.8	Clinical aspects of antiviral agents used in the treatment of hepatitis C	523	21.5.2	Agents that inhibit tubulin depolymerization	566
Box 20.9	The COVID-19 pandemic	524	21.6	Inhibitors of signalling pathways	567
Box 20.10	The 3C-like protease of SARS-CoV-2 as a target for novel antiviral agents	526	21.6.1	Inhibition of farnesyl transferase and the Ras protein	567
			21.6.1.1	Inhibition of farnesyl transferase	567
			21.6.1.2	Inhibition of KRAS	569
			21.6.2	Protein kinase inhibitors	570
			21.6.3	Receptor antagonists of the hedgehog signalling pathway	570
21	Anticancer agents	533	21.7	Miscellaneous enzyme inhibitors	573
21.1	Cancer: an introduction	533	21.7.1	Matrix metalloproteinase inhibitors	573
21.1.1	Definitions	533	21.7.2	Proteasome inhibitors	574
21.1.2	Causes of cancer	533	21.7.3	Histone deacetylase inhibitors	577
21.1.3	Genetic faults leading to cancer: proto-oncogenes and oncogenes	533	21.7.4	Inhibitors of poly ADP ribose polymerase	578
21.1.3.1	Activation of proto-oncogenes	533	21.7.5	Isocitrate dehydrogenase inhibitors	584
21.1.3.2	Inactivation of tumour suppression genes (anti-oncogenes)	533	21.7.6	Inhibitors for Enhancer of Zeste homologue 2	588
21.1.3.3	The consequences of genetic defects	534	21.7.7	Other enzyme targets	590
21.1.4	Abnormal signalling pathways	534	21.8	Agents affecting pro-survival and pro-apoptotic proteins	590
21.1.5	Insensitivity to growth-inhibitory signals	534	21.9	Agents affecting nuclear transport proteins	592
21.1.6	Abnormalities in cell cycle regulation	534	21.10	Miscellaneous anticancer agents	592
21.1.7	Apoptosis and the p53 protein	535	21.10.1	Synthetic agents	593
21.1.8	Telomeres	537	21.10.2	Natural products	594
21.1.9	Angiogenesis	538	21.10.3	Modulation of transcription factor-coactivator interactions	595
21.1.10	Tissue invasion and metastasis	539	21.10.4	PROTAC	596
21.1.11	Treatment of cancer	539	21.11	Photodynamic therapy	597
21.1.12	Resistance	540	21.12	Radionuclide therapy	598
21.2	Drugs acting directly on nucleic acids	541	21.13	The role of biologics in anticancer therapy	598
21.2.1	Intercalating agents	541	Box 21.1	Clinical aspects of intercalating agents	542
21.2.2	Non-intercalating agents that inhibit the action of topoisomerase enzymes on DNA	543	Box 21.2	Clinical aspects of non-intercalating agents inhibiting the action of topoisomerase enzymes on DNA	544
21.2.2.1	Podophyllotoxins	543	Box 21.3	Clinical aspects of alkylating and metallating agents	548
21.2.2.2	Camptothecins	543	Box 21.4	Clinical aspects of antimetabolites	555
21.2.3	Alkylating and metallating agents	544	Box 21.5	Clinical aspects of hormone-based therapies	563
21.2.3.1	Nitrogen mustards	544	Box 21.6	Clinical aspects of drugs acting on structural proteins	566
21.2.3.2	Cisplatin and cisplatin analogues: metallating agents	546	Box 21.7	Clinical effects of smoothened inhibitors of the hedgehog signalling pathway	573
21.2.3.3	CC 1065 analogues	546	Box 21.8	Clinical aspects of PARP-1 inhibitors	587
21.2.3.4	Ecteinascidins	546	Box 21.9	Clinical effects of isocitrate dehydrogenase inhibitors	588
21.2.3.5	Other alkylating agents	549	Box 21.10	Clinical effects of tazemetostat	589
21.2.4	Chain cutters	549	Box 21.11	Clinical aspects of exportin 1 inhibitors	594
21.3	Drugs acting on enzymes: antimetabolites	549	22	Protein kinase inhibitors as anticancer agents	601
21.3.1	Dihydrofolate reductase inhibitors	549	22.1	Introduction	601
21.3.2	Inhibitors of thymidylate synthase	550	22.1.1	The active site of protein kinases	601
21.3.3	Inhibitors of ribonucleotide reductase	552	22.1.2	Classification of protein kinase inhibitors	602
21.3.4	Inhibitors of adenosine deaminase	552	22.1.3	Selectivity and resistance	603
21.3.5	Cytidine deaminase inhibitors	553	22.2	Kinase inhibitors of the epidermal growth factor receptor (EGFR)	603
21.3.6	Inhibitors of DNA polymerases	553			
21.3.7	Purine antagonists	553			
21.3.8	DNA methyltransferase inhibitors	553			
21.4	Hormone-based therapies	557			
21.4.1	Glucocorticoids, estrogens, progestins, and androgens	557			
21.4.2	Luteinizing hormone-releasing hormone receptor agonists and antagonists	559			
21.4.3	Anti-estrogens	559			
21.4.4	Anti-androgens	559			
21.4.5	Aromatase inhibitors	560			
21.4.6	Mitotane	562			
21.4.7	Somatostatin receptor agonists	562			
21.5	Drugs acting on structural proteins	564			

22.3 Kinase inhibitors of Abelson tyrosine kinase, c-KIT, PDGFR, and SRC	608	Box 22.12 Clinical aspects of kinase inhibitors for neurotrophic tropomyosin receptor kinase (NTRK or TRK) and ROS1	637
22.4 Kinase inhibitors of c-KIT and PDGFR	612	Box 22.13 Clinical aspects of miscellaneous kinase inhibitors	639
22.5 Inhibitors of cyclin-dependent kinases (CDKs)	613	Box 22.14 Design of sorafenib	643
22.6 Kinase inhibitors of the MAPK signal transduction pathway	616	Box 22.15 Clinical aspects of multi-target kinase inhibitors and inhibitors of protein–protein interactions	645
22.6.1 BRAF inhibitors	616		
22.6.2 MEK inhibitors	617		
22.7 Kinase inhibitors of PI3K-PIP ₃ pathways	620	23 Antibodies and other biologics	649
22.7.1 Introduction	620	23.1 The immune system	649
22.7.2 Inhibitors of phosphoinositide 3-kinase	620	23.1.1 Introduction	649
22.7.3 Inhibitors of Bruton's tyrosine kinase	623	23.1.2 Phagocytes	649
22.8 Kinase inhibitors of anaplastic lymphoma kinase (ALK)	627	23.1.3 B-cells, plasma cells, and antibody production	649
22.9 Kinase inhibitors of RET and KIF5B-RET	631	23.1.4 T-cell lymphocytes	649
22.10 Kinase inhibitors of Janus kinase	632	23.1.5 The complement system	650
22.11 Kinase inhibitors of vascular endothelial growth factor receptor (VEGFR)	633	23.1.6 Antibodies	650
22.12 Kinase inhibitors of fibroblast growth factor receptor (FGFR)	633	23.2 Antibody manufacture	651
22.13 Kinase inhibitors of neurotrophic tropomyosin receptor tyrosine kinase (NTRK or TRK) and ROS1	635	23.3 Monoclonal antibodies as anticancer agents	653
22.14 Kinase inhibitors of FMS-like tyrosine kinase 3 (FLT3)	637	23.3.1 Introduction	653
22.15 Kinase inhibitors of colony-stimulating factor-1 receptor (CSF-1R)	639	23.3.2 Monoclonal antibodies targeting the HER family of receptors	654
22.16 Kinase inhibitors of the hepatocyte growth factor receptor (HGFR or c-MET)	640	23.3.3 Antibodies targeting VEGF and VEGFR	654
22.17 Multi-receptor tyrosine kinase inhibitors	643	23.3.4 Antibodies targeting the RANK ligand	654
22.18 Kinase inhibition involving protein–protein binding interactions	645	23.3.5 Antibodies targeting the glycolipid GD2	655
22.19 Kinase degradation induced by protein–protein binding interactions	646	23.3.6 Antibodies targeting interleukins	655
22.20 Summary	646	23.3.7 Antibodies targeting CD proteins in B-cells	656
Box 22.1 General synthesis of gefitinib and related analogues	604	23.3.7.1 Antibodies targeting CD52	656
Box 22.2 Clinical aspects of EGF-receptor kinase inhibitors	607	23.3.7.2 Antibodies targeting CD20	656
Box 22.3 General synthesis of imatinib and analogues	609	23.3.7.3 Antibodies targeting CD19	656
Box 22.4 Clinical aspects of kinase inhibitors acting on Bcr-Abl, c-KIT, and PDGFR	613	23.3.8 Antibodies targeting CD proteins on plasma cells	658
Box 22.5 Clinical aspects of cyclin-dependent kinase inhibitors	615	23.3.8.1 Antibodies targeting SLAMF7 (CD319)	658
Box 22.6 Clinical aspects of kinase inhibitors affecting the MAPK signal transduction pathway	619	23.3.8.2 Antibodies targeting CD38	658
Box 22.7 Clinical aspects of kinase inhibitors targeting the PI3K-PIP ₃ pathway	625	23.3.9 Antibodies targeting the CCR4 receptor	659
Box 22.8 Clinical aspects of anaplastic lymphoma kinase (ALK) inhibitors	630	23.3.10 Monoclonal antibodies acting on immune checkpoints	660
Box 22.9 Clinical aspects of kinase inhibitors acting on RET and KIF5B-RET	632	23.3.10.1 Introduction	660
Box 22.10 Clinical aspects of Janus kinase inhibitors	632	23.3.10.2 Antibodies targeting CTLA-4	660
Box 22.11 Clinical aspects of fibroblast growth factor inhibitors	635	23.3.10.3 Antibodies targeting the programmed death receptor (PD-1)	660
		23.3.10.4 Antibodies targeting programmed death ligand 1	661
		23.4 Antibody–drug conjugates	662
		23.4.1 Introduction	662
		23.4.2 Antibody–drug conjugates targeting HER2	664
		23.4.3 Antibody–drug conjugates targeting trophoblast cell-surface antigen	665
		23.4.4 Antibody–drug conjugates targeting nectin 4	666
		23.4.5 Antibody–drug conjugates targeting B-cells	667
		23.4.5.1 Antibodies targeting CD19	667
		23.4.5.2 Antibodies targeting CD20	667
		23.4.5.3 Antibodies targeting CD22	667
		23.4.5.4 Antibodies targeting CD30	668
		23.4.5.5 Antibodies targeting CD33	669
		23.4.5.6 Antibodies targeting CD79	669
		23.4.5.7 Antibodies targeting CD142	670
		23.5 Antibody-directed enzyme prodrug therapy (ADEPT)	671
		23.6 Antibody-directed abzyme prodrug therapy (ADAPT)	672
		23.7 Gene-directed enzyme prodrug therapy (GDEPT)	672
		23.8 Other forms of anticancer therapy	673
		23.8.1 Gene therapy	673

xxii Detailed contents

23.8.2	Antisense therapy	673	24.13	Anticholinesterase drugs	696
23.9	Protein therapy	673	24.13.1	Carbamates	696
23.10	Viral therapy	673	24.13.1.1	Physostigmine	696
Box 23.1	Examples of antibodies in clinical use	652	24.13.1.2	Analogues of physostigmine	697
Box 23.2	Gemtuzumab ozogamicin: an antibody–drug conjugate	669	24.13.2	Organophosphorus compounds	699
			24.13.2.1	Nerve agents	699
			24.13.2.2	Medicines	700
			24.13.2.3	Insecticides	700
24	Cholinergics, anticholinergics, and anticholinesterases	676	24.14	Pralidoxime: an organophosphate antidote	700
24.1	The peripheral nervous system	676	24.15	Anticholinesterases as ‘smart drugs’	701
24.2	Motor nerves of the peripheral nervous system	676	24.15.1	Acetylcholinesterase inhibitors	701
24.2.1	The somatic motor nervous system	677	24.15.2	Dual-action agents acting on the acetylcholinesterase enzyme	702
24.2.2	The autonomic motor nervous system	677	24.15.3	Multi-targeted agents acting on the acetylcholinesterase enzyme and the muscarinic M ₂ receptor	703
24.2.3	The enteric system	677	Box 24.1	Clinical applications for muscarinic antagonists	688
24.2.4	Defects in motor nerve transmission	678	Box 24.2	Muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD)	689
24.3	The cholinergic system	678	Box 24.3	Mosses play it smart	702
24.3.1	The cholinergic signalling system	678	25	Drugs acting on the adrenergic nervous system	707
24.3.2	Presynaptic control systems	678	25.1	The adrenergic nervous system	707
24.3.3	Co-transmitters	679	25.1.1	Peripheral nervous system	707
24.4	Agonists at the cholinergic receptor	679	25.1.2	Central nervous system	707
24.5	Acetylcholine: structure, SAR, and receptor binding	680	25.2	Adrenergic receptors	707
24.6	The instability of acetylcholine	682	25.2.1	Types of adrenergic receptor	707
24.7	Design of acetylcholine analogues	682	25.2.2	Distribution of receptors	708
24.7.1	Steric shields	682	25.3	Endogenous agonists for the adrenergic receptors	708
24.7.2	Electronic effects	682	25.4	Biosynthesis of catecholamines	708
24.7.3	Combining steric and electronic effects	683	25.5	Metabolism of catecholamines	709
24.8	Clinical uses for cholinergic agonists	683	25.6	Neurotransmission	710
24.8.1	Muscarinic agonists	683	25.6.1	The neurotransmission process	710
24.8.2	Nicotinic agonists	684	25.6.2	Co-transmitters	710
24.9	Antagonists of the muscarinic cholinergic receptor	684	25.6.3	Presynaptic receptors and control	710
24.9.1	Actions and uses of muscarinic antagonists	684	25.7	Drug targets	710
24.9.2	Muscarinic antagonists	685	25.8	The adrenergic binding site	712
24.9.2.1	Atropine and hyoscine	685	25.9	Structure–activity relationships (SARs)	712
24.9.2.2	Structural analogues of atropine and hyoscine	686	25.9.1	Important binding groups on catecholamines	712
24.9.2.3	Simplified analogues of atropine	686	25.9.2	Selectivity for α - versus β -adrenoceptors	713
24.9.2.4	Quinuclidine muscarinic agents	687	25.10	Adrenergic agonists	714
24.9.2.5	Other muscarinic antagonists	687	25.10.1	General adrenergic agonists	714
24.10	Antagonists of the nicotinic cholinergic receptor	687	25.10.2	α_1 -, α_2 -, β_1 -, and β_3 -agonists	715
24.10.1	Applications of nicotinic antagonists	687	25.10.3	β_2 -agonists and the treatment of asthma	715
24.10.2	Nicotinic antagonists	687	25.11	Adrenergic receptor antagonists	718
24.10.2.1	Curare and tubocurarine	687	25.11.1	General α/β -blockers	718
24.10.2.2	Decamethonium and suxamethonium	691	25.11.2	α -blockers	718
24.10.2.3	Steroidal neuromuscular blocking agents	691	25.11.3	β -blockers as cardiovascular drugs	719
24.10.2.4	Atracurium and mivacurium	692	25.11.3.1	First-generation β -blockers	719
24.10.2.5	Other nicotinic antagonists	693	25.11.3.2	Structure–activity relationships of aryloxypropanolamines	720
24.11	Receptor structures	694	25.11.3.3	Selective β_1 -blockers (second-generation β -blockers)	720
24.12	Anticholinesterases and acetylcholinesterase	694	25.11.3.4	Short-acting β -blockers	722
24.12.1	Effect of anticholinesterases	694	25.12	Other drugs affecting adrenergic transmission	723
24.12.2	Structure of the acetylcholinesterase enzyme	694	25.12.1	Drugs that affect the biosynthesis of adrenergics	723
24.12.3	The active site of acetylcholinesterase	695			
24.12.3.1	Crucial amino acids within the active site	695			
24.12.3.2	Mechanism of hydrolysis	695			

25.12.2	Drugs inhibiting the uptake of noradrenaline into storage vesicles	724	27 Anti-ulcer agents	754
25.12.3	Release of noradrenaline from storage vesicles	724	27.1 Peptic ulcers	754
25.12.4	Reuptake inhibitors of noradrenaline into presynaptic neurons	724	27.1.1 Definition	754
25.12.5	Inhibition of metabolic enzymes	726	27.1.2 Causes	754
Box 25.1	Clinical aspects of adrenergic agents	709	27.1.3 Treatment	754
Box 25.2	Synthesis of salbutamol	716	27.1.4 Gastric acid release	754
Box 25.3	Synthesis of aryloxypropanolamines	720	27.2 H₂-Antagonists	755
Box 25.4	Clinical aspects of β -blockers	721	27.2.1 Histamine and histamine receptors	756
26 The opioid analgesics		729	27.2.2 Searching for a lead	756
26.1	History of opium	729	27.2.2.1 Histamine	756
26.2	The active principle: morphine	729	27.2.2.2 N ^m -Guanylhistamine	757
26.2.1	Isolation of morphine	729	27.2.3 Developing the lead: a chelation bonding theory	759
26.2.2	Structure and properties	729	27.2.4 From partial agonist to antagonist: the development of burimamide	760
26.3	Structure–activity relationships	730	27.2.5 Development of metiamide	762
26.4	The molecular target for morphine: opioid receptors	732	27.2.6 Development of cimetidine	764
26.5	Morphine: pharmacodynamics and pharmacokinetics	733	27.2.7 Cimetidine	765
26.6	Morphine analogues	734	27.2.7.1 Biological activity	765
26.6.1	Variation of substituents	734	27.2.7.2 Structure and activity	766
26.6.2	Drug extension	734	27.2.7.3 Metabolism	766
26.6.3	Simplification or drug dissection	736	27.2.8 Further studies of cimetidine analogues	766
26.6.3.1	Removing ring E	736	27.2.8.1 Conformational isomers	766
26.6.3.2	Removing ring D	736	27.2.8.2 Desolvation	767
26.6.3.3	Removing rings C and D	737	27.2.8.3 Development of the nitroketeneaminal binding group	768
26.6.3.4	Removing rings B, C, and D	737	27.2.9 Further H ₂ -antagonists	769
26.6.3.5	Removing rings B, C, D, and E	739	27.2.9.1 Ranitidine	769
26.6.4	Rigidification	739	27.2.9.2 Famotidine and nizatidine	770
26.7	Agonists and antagonists	742	27.2.9.3 H ₂ -Antagonists with prolonged activity	771
26.8	Endogenous opioid peptides and opioids	744	27.2.10 Comparison of H ₁ - and H ₂ -antagonists	771
26.8.1	Endogenous opioid peptides	744	27.2.11 H ₂ Receptors and H ₂ -antagonists	771
26.8.2	Analogues of enkephalins and δ -selective opioids	745	27.3 Proton pump inhibitors (PPIs)	772
26.8.3	Binding theories for enkephalins	747	27.3.1 Parietal cells and the proton pump	772
26.8.4	Inhibitors of peptidases	747	27.3.2 PPIs	773
26.8.5	Endogenous morphine	748	27.3.3 Mechanism of inhibition	774
26.9	The future	748	27.3.4 Metabolism of PPIs	775
26.9.1	The message–address concept	748	27.3.5 Design of omeprazole and esomeprazole	775
26.9.2	Receptor dimers	748	27.3.6 Other PPIs	777
26.9.3	Selective opioid agonists versus multi-targeted opioids	750	27.4 <i>Helicobacter pylori</i> and the use of antibacterial agents	778
26.9.4	Peripheral-acting opioids	750	27.4.1 Discovery of <i>Helicobacter pylori</i>	778
26.9.5	Biased agonists	750	27.4.2 Treatment	778
26.10	Case study: design of nalfurafine	750	27.5 Traditional and herbal medicines	779
Box 26.1	Clinical aspects of morphine	730	Box 27.1 Synthesis of cimetidine	765
Box 26.2	Synthesis of N-alkylated morphine analogues	735	Box 27.2 Synthesis of omeprazole and esomeprazole	777
Box 26.3	Opioids as antidiarrhoeal agents	740	28 Cardiovascular drugs	781
Box 26.4	Synthesis of the orvinols	741	28.1 Introduction	781
Box 26.5	A comparison of opioids and their effects on opioid receptors	744	28.2 The cardiovascular system	781
Box 26.6	Design of naltrindole	746	28.3 Antihypertensives affecting the activity of the RAAS system	782
			28.3.1 Introduction	782
			28.3.2 Renin inhibitors	783
			28.3.3 ACE inhibitors	784
			28.3.4 Angiotensin receptor antagonists	784
			28.3.5 Mineralocorticoid receptor antagonists	787
			28.3.6 Dual-action agents	787

28.4	Endothelin receptor antagonists as antihypertensive agents	787	28.9.2.2	PAR-1 antagonists	805
28.4.1	Endothelins and endothelin receptors	787	28.9.2.3	P2Y ₁₂ -Antagonists	806
28.4.2	Endothelin antagonists	788	28.9.2.4	GpIIb/IIIa antagonists	807
28.4.3	Dual-action agents	788	28.9.3	Fibrinolytic drugs	808
28.5	Vasodilators	789	Box 28.1	Synthesis of dihydropyridines	794
28.5.1	Modulators of soluble guanylate cyclase	789	■	Case study 7 Steroidal anti-inflammatory agents	811
28.5.2	Phosphodiesterase type 5 inhibitors	791	■	Case study 8 Current research into antidepressant agents	821
28.5.3	Neprilysin inhibitors	791	■	Case study 9 The design and development of aliskiren	826
28.5.4	Prostacyclin agonists	792	■	Case study 10 Factor Xa inhibitors	832
28.5.5	Miscellaneous vasodilators	792	■	Case study 11 Reversible inhibitors of HCV NS3-4A protease	838
28.6	Calcium entry blockers	793	Appendix 1	Essential amino acids	843
28.6.1	Introduction	793	Appendix 2	The standard genetic code	844
28.6.2	Dihydropyridines	794	Appendix 3	Statistical data for QSAR	845
28.6.3	Phenylalkylamines	796	Appendix 4	The action of nerves	848
28.6.4	Benzothiazepines	796	Appendix 5	Microorganisms	852
28.7	Funny ion channel inhibitors	797	Appendix 6	Drugs and their trade names	854
28.8	Lipid-regulating agents	798	Appendix 7	Trade name (drug name)	865
28.8.1	Statins	798	Appendix 8	Potential hydrogen bond donors (HBDs) and hydrogen bond acceptors (HBAs) in common functional groups	878
28.8.2	Fibrates	799	Appendix 9	Using the Protein Data Bank	880
28.8.3	Dual- and pan-PPAR agonists	799	Glossary		883
28.8.4	Antisense drugs	799	General Further Reading		905
28.8.5	Inhibitors of transfer proteins	801	Index		907
28.8.6	Antibodies as lipid-lowering agents	801			
28.8.7	ATP citrate lyase inhibitors	802			
28.9	Antithrombotic agents	802			
28.9.1	Anticoagulants	803			
28.9.1.1	Introduction	803			
28.9.1.2	Direct thrombin inhibitors	803			
28.9.1.3	Factor Xa inhibitors	804			
28.9.2	Antiplatelet agents	805			
28.9.2.1	Introduction	805			

List of Boxes

General interest

3.1	The external control of enzymes by nitric oxide	38
7.1	A cure for antifreeze poisoning	90
7.2	Irreversible inhibition for the treatment of obesity	91
7.3	Suicide substrates	95
7.4	Designing drugs to be isozyme selective	96
7.5	Action of toxins on enzymes	98
7.6	Kinase inhibitors	99
8.1	An unexpected agonist	106
8.2	Estradiol and the estrogen receptor	109
10.1	Antidepressant drugs acting on transport proteins	135
10.2	Targeting transcription factor—coactivator interactions	138
10.3	Cyclodextrins as drug scavengers	149
11.1	Metabolism of an antiviral agent	162
12.1	Recently discovered targets: the caspases	186
12.2	Pitfalls in choosing particular targets	188
12.3	Early tests for potential toxicity	189
12.4	Selective optimization of side activities (SOSA)	199
12.5	Natural ligands as lead compounds	200
12.6	Examples of serendipity	201
12.7	The use of NMR spectroscopy in finding lead compounds	203
12.8	Click chemistry <i>in situ</i>	204
12.9	Fragment-based design of a scaffold using X-ray crystallography	205
13.1	Converting an enzyme substrate to an inhibitor by extension tactics	225
13.2	Simplification	230
13.3	Rigidification tactics in drug design	233
13.4	The structure-based drug design of crizotinib	236
14.1	The use of bio-isosteres to increase absorption	244
14.2	Shortening the lifetime of a drug	248
14.3	Identifying and replacing potentially toxic groups	250
14.4	Varying esters in prodrugs	252
14.5	Prodrugs masking toxicity and side effects	254
14.6	Prodrugs to improve water solubility	255
15.1	Drug metabolism studies and drug design	267
16.1	Examples of scaffolds	313
17.1	Energy minimization of apomorphine	330
17.2	Study of HOMO and LUMO orbitals	334

17.3	Finding conformations of cyclic structures by molecular dynamics	337
17.4	Identification of an active conformation	343
17.5	Constructing a receptor map	357
17.6	Designing a non-steroidal glucocorticoid agonist	365
18.1	Altering log <i>P</i> to remove central nervous system side effects	372
18.2	Insecticidal activity of diethyl phenyl phosphates	375
18.3	Hansch equation for a series of antimalarial compounds	377
19.1	Sulphonamide analogues with reduced toxicity	401
19.2	Treatment of intestinal infections	402
19.5	The isoxazolyl penicillins	414
19.7	Ampicillin prodrugs	416
19.22	Nitroimidazoles in the treatment of sleeping sickness	455
19.24	Organoarsenicals as antiparasitic drugs	461
20.9	The COVID-19 pandemic	524
20.10	The 3C-like protease of SARS-CoV-2 as a target for novel antiviral agents	526
22.14	Design of sorafenib	643
23.2	Gemtuzumab ozogamicin: an antibody–drug conjugate	669
24.3	Mosses play it smart	702
26.3	Opioids as antidiarrhoeal agents	740
26.5	A comparison of opioids and their effects on opioid receptors	744
26.6	Design of naltrindole	746

Synthesis

15.2	Synthesis of ebalzotan	276
15.3	Synthesis of ICI D7114	276
16.2	Dynamic combinatorial synthesis of vancomycin dimers	324
19.9	Synthesis of 3-methylated cephalosporins	421
19.15	Synthesis of plazomicin	439
19.16	Synthesis of minocycline and amadacycline	443
19.17	Synthesis of eravacycline	444
19.20	Synthesis of ciprofloxacin	452
20.5	The use of a chiral centre to control the absolute configuration of a second chiral centre	495
22.1	General synthesis of gefitinib and related analogues	604

xxvi List of boxes

22.3	General synthesis of imatinib and analogues	609	20.7	Clinical aspects of cell entry inhibitors	501
25.2	Synthesis of salbutamol	716	20.8	Clinical aspects of antiviral agents used in the treatment of hepatitis C	523
25.3	Synthesis of aryloxypropanolamines	720	21.1	Clinical aspects of intercalating agents	542
26.2	Synthesis of <i>N</i> -alkylated morphine analogues	735	21.2	Clinical aspects of non-intercalating agents inhibiting the action of topoisomerase enzymes on DNA	544
26.4	Synthesis of the orvinols	741	21.3	Clinical aspects of alkylating and metallating agents	548
27.1	Synthesis of cimetidine	765	21.4	Clinical aspects of antimetabolites	555
27.2	Synthesis of omeprazole and esomeprazole	777	21.5	Clinical aspects of hormone-based therapies	563
28.1	Synthesis of dihydropyridines	794	21.6	Clinical aspects of drugs acting on structural proteins	566
CS2.1	Synthesis of captopril and enalaprilat	286	21.7	Clinical effects of smoothened inhibitors of the hedgehog signalling pathway	573
CS4.1	Synthesis of oxamniquine	298	21.8	Clinical aspects of PARP-1 inhibitors	587

Clinical correlation

19.3	Clinical properties of benzylpenicillin and phenoxymethylpenicillin	406	21.11	Clinical aspects of exportin 1 inhibitors	594
19.4	<i>Pseudomonas aeruginosa</i>	409	22.2	Clinical aspects of EGF-receptor kinase inhibitors	607
19.6	Clinical aspects of β -lactamase-resistant penicillins	414	22.4	Clinical aspects of kinase inhibitors acting on Bcr-Abl, c-KIT, and PDGFR	613
19.8	Clinical aspects of broad-spectrum penicillins	417	22.5	Clinical aspects of cyclin-dependent kinase inhibitors	615
19.10	Clinical aspects of cephalosporins	424	22.6	Clinical aspects of kinase inhibitors affecting the MAPK signal transduction pathway	619
19.11	Clinical aspects of miscellaneous β -lactam antibiotics	426	22.7	Clinical aspects of kinase inhibitors targeting the PI3K-PIP ₃ pathway	625
19.12	Clinical aspects of cycloserine, bacitracin, and vancomycin	435	22.8	Clinical aspects of anaplastic lymphoma kinase (ALK) inhibitors	630
19.13	Clinical aspects of drugs acting on the plasma membrane	436	22.9	Clinical aspects of kinase inhibitors acting on RET and KIF5B-RET	632
19.14	Clinical aspects of aminoglycosides	438	22.10	Clinical aspects of Janus kinase inhibitors	632
19.18	Clinical aspects of tetracyclines and chloramphenicol	445	22.11	Clinical aspects of fibroblast growth factor inhibitors	635
19.19	Clinical aspects of macrolides, lincosamides, streptogramins, oxazolidinones, and pleuromutilins	450	22.12	Clinical aspects of kinase inhibitors for neurotrophic tropomyosin receptor kinase (NTRK or TRK) and ROS1	637
19.21	Clinical aspects of quinolones and fluoroquinolones	453	22.13	Clinical aspects of miscellaneous kinase inhibitors	639
19.23	Clinical aspects of rifamycins and miscellaneous agents	457	22.15	Clinical aspects of multi-target kinase inhibitors and inhibitors of protein-protein interactions	645
20.1	Clinical aspects of inhibitors targeting viral DNA polymerase or the DNA terminase complex	472	23.1	Examples of antibodies in clinical use	652
20.2	Clinical aspects of antiviral drugs used against HIV	476	24.1	Clinical applications for muscarinic antagonists	688
20.3	Clinical aspects of reverse transcriptase inhibitors	480	24.2	Muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD)	689
20.4	Clinical aspects of protease inhibitors	481	25.1	Clinical aspects of adrenergic agents	709
20.6	Clinical aspects of integrase inhibitors	496	25.4	Clinical aspects of β -blockers	721
			26.1	Clinical aspects of morphine	730
			CS3.1	Clinical properties of artemisinin and analogues	292
			CS7.1	Clinical aspects of glucocorticoids	819